title: Investigation of nano lipid vesicles of methotrexate for anti-rheumatoid activity.
abstract: BACKGROUND
  The purpose of this study was to formulate and evaluate nano lipid vesicles of methotrexate (MTX) for its anti-rheumatoid activity.
  
  
  METHODS
  In this study the principle of both active as well as passive targeting using MTX-loaded stealth liposomes as per the magic gun approach was followed. Stealth liposomes of MTX were prepared by thin-film hydration method using a PEGylated phospholipid-like DSPE-MPEG 2000. Similarly, conventional liposomes were prepared using phospholipids like DPPC and DSPC. Conventional liposomes were coated with a hydrophilic biocompatible polymer like chitosan. They were investigated for their physical properties and in vitro release profile. Further, in vivo screening of the formulations for their anti-rheumatoid efficacy was carried out in rats. Rheumatoid arthritis was induced in male Wistar-Lewis rats using complete Freund's adjuvant (1 mg/mL Mycobacterium tuberculosis, heat killed in mineral oil).
  
  
  RESULTS
  It was found that chitosan coating of the conventional liposomes increased the physical stability of the liposomal suspension as well as its entrapment efficiency. The size of the unsonicated lipid vesicles was found to be in the range of 8-10 μm, and the sonicated lipid vesicles in the range of 210-260 nm, with good polydispersity index. Further, chitosan-coated conventional liposomes and the PEGylated liposomes released the drug for a prolonged period of time, compared to the uncoated conventional liposomes. It was found that there was a significant reduction in edema volume in the rat group administered with the test stealth liposomal formulations and chitosan-coated conventional liposomes (PEGylated and chitosan-coated conventional) compared to that of the control and standard (administered with free MTX) group of rats. PEGylated liposomes showed almost equal efficacy as that of the chitosan-coated conventional liposomes.
  
  
  CONCLUSIONS
  Lipid nano vesicles of MTX can be administered by intravenous route, whereby the drug selectively reaches the target site with reduced toxicity to other organs.
authors.affiliation: Department of Pharmaceutics, Nitte University, NGS M Institute of Pharmaceutical Sciences, Paneer, Deralakatte, Mangalore, Karnataka, India. prabhuprashu@rediffmail.com
authors.forename: Prabhakara
authors.initials: P
authors.lastname: Prabhu
authors.forename: Rakshith
authors.initials: R
authors.lastname: Shetty
authors.forename: Marina
authors.initials: M
authors.lastname: Koland
authors.forename: K
authors.initials: K
authors.lastname: Vijayanarayana
authors.forename: K K
authors.initials: KK
authors.lastname: Vijayalakshmi
authors.forename: M Harish
authors.initials: MH
authors.lastname: Nairy
authors.forename: G S
authors.initials: GS
authors.lastname: Nisha
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D001169:Arthritis, Experimental / Q000188:drug therapy / Q000378:metabolism; D002152:Calorimetry, Differential Scanning; D048271:Chitosan / Q000737:chemistry; D004355:Drug Stability; D007249:Inflammation / Q000188:drug therapy; D008081:Liposomes / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D053758:Nanoparticles / Q000737:chemistry*; D010316:Particle Size; D051381:Rats; D017208:Rats, Wistar
chemical_list: D018501:Antirheumatic Agents; D008081:Liposomes; D048271:Chitosan; D008727:Methotrexate